ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Bayesian selection of lipidome dynamics features for a K-nearest neighbors (KNN) classifier model of tumor response in patients with advanced gastrointestinal adenocarcinoma undergoing systemic treatment.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDysregulated lipid metabolism is common in patients with gastrointestinal (GI) cancer. This study investigated the ability of plasma lipidome variation during systemic treatment to classify GI cancer patients according to tumor response.
methodsNon-targeted plasma lipidomics with LC-qTOF mass spectrometry was conducted in patients with advanced GI adenocarcinomas before and after three months of systemic standard-of-care antitumor treatment. Bayesian ANOVA with repeated measures and an uninformative prior was used to screen for analytes whose before-and-after variation could be associated with tumor response. Suitable candidates with a Bayes Factor (BF) > 7 for the interaction were used to train a KNN model to classify patients as responders (PR + CR) vs. non-responders (PD + SD) according to RECIST 1.1 criteria.
resultsThirty patients were included (18 colorectal, 6 gastric, 6 biliopancreatic). The cohort included 10 responders (all partial responses, 33%) and 20 non-responders (14 stable disease, 6 progressive disease). Plasma lipidomics identified 262 analytes on 10 lipid species: phosphatidylcholines (PCs), non-polar and polar lyso-PCs, sphingomyelins, lysophosphatidylethanolamines, cholesterol esters, acylglycerides, fatty acids, hormones, and bile acids. An increase in abundance after treatment of five PCs (PC32:2, PC33:2, PC36:2, PC36:5, PC38:5) was associated with tumor response (BF > 7 for interaction). After excluding collinear PCs (retaining PC32:2, PC33:2, PC36:2), a KNN model (optimized: k = 7, Manhattan distance, inverse weighting, LOOCV) achieved consistent performance over 20 runs (mean ± SD): AUC 0.86 ± 0.23; Precision 0.76 ± 0.17; Recall 0.81 ± 0.15; F1 score 0.80 ± 0.13; MCC 0.66 ± 0.23. None of the other nine lipid classes contributed more than one analyte with a BF > 7 for the interaction with tumor response.
conclusionsTumor response is associated with variations in plasma lipidome in patients with advanced GI cancer. The plasma abundance of PCs increased after treatment in responder patients, suggesting that further investigation may be warranted on PCs as a potential biomarker.
Indexed as
Identifiers
41408017What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.